143 related articles for article (PubMed ID: 37969863)
1. Safety of Plasmapheresis in Donors with Low IgG Levels: Results of a Prospective, Controlled Multicentre Study.
Moog R; Laitinen T; Taborski U
Transfus Med Hemother; 2022 Sep; 49(5):271-279. PubMed ID: 37969863
[TBL] [Abstract][Full Text] [Related]
2. Donor safety in an individualized plasmapheresis program - Results of an interim analysis.
Taborski U; Laitinen T
Transfus Apher Sci; 2022 Oct; 61(5):103446. PubMed ID: 35461780
[TBL] [Abstract][Full Text] [Related]
3. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
[TBL] [Abstract][Full Text] [Related]
4. A prospective trial on the safety of long-term intensive plasmapheresis in donors.
Bechtloff S; Tran-My B; Haubelt H; Stelzer G; Anders C; Hellstern P
Vox Sang; 2005 Apr; 88(3):189-95. PubMed ID: 15787729
[TBL] [Abstract][Full Text] [Related]
5. Serum IgG and IgM levels in new and regular long-term plasmapheresis donors.
Burgin M; Hopkins G; Moore B; Nasser J; Richardson A; Minchinton R
Med Lab Sci; 1992 Dec; 49(4):265-70. PubMed ID: 1339930
[TBL] [Abstract][Full Text] [Related]
6. The effect of donation frequency on donor health in blood donors donating plasma by plasmapheresis: study protocol for a randomized controlled trial.
Haugen M; Magnussen K; Aarsland TE; Nissen-Meyer LSH; Strand TA
Trials; 2024 Mar; 25(1):175. PubMed ID: 38468338
[TBL] [Abstract][Full Text] [Related]
7. Donor vigilance data of a blood transfusion service: A multicenter analysis.
Burkhardt T; Dimanski B; Karl R; Sievert U; Karl A; Hübler C; Tonn T; Sopvinik I; Ertl H; Moog R
Transfus Apher Sci; 2015 Oct; 53(2):180-4. PubMed ID: 26074050
[TBL] [Abstract][Full Text] [Related]
8. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.
Thijsen A; Davison TE; Speedy J; Hoad V; Masser B
Vox Sang; 2021 Mar; 116(3):273-280. PubMed ID: 32702163
[TBL] [Abstract][Full Text] [Related]
9. The risks of low hemoglobin deferral in a large retrospective cohort of plasmapheresis donors and the influence factors of return for a subsequent donation in China.
Xiao G; Dong D; Wang Y; Li C; Huang GT; Yang H; Huang J; Chen F
PeerJ; 2023; 11():e14999. PubMed ID: 36935911
[TBL] [Abstract][Full Text] [Related]
10. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
[TBL] [Abstract][Full Text] [Related]
11. Safety and protection of plasma donors: A scoping review and evidence gap map.
Schroyens N; D'aes T; De Buck E; Mikkelsen S; Tiberghien P; van den Hurk K; Erikstrup C; Compernolle V; Van Remoortel H
Vox Sang; 2024 Feb; 119(2):110-120. PubMed ID: 37814964
[TBL] [Abstract][Full Text] [Related]
12. Effect of Plasma Unit Weight and Donor Sex on Post-Donation Citrate Level: An Experimental Study on Plasmapheresis Donors.
Marraccini C; Schiroli D; Mancuso P; Molinari G; Razzoli A; Gavioli G; Fasano T; Baricchi R; Rossi PG; Merolle L
Transfus Med Hemother; 2023 Dec; 50(6):491-501. PubMed ID: 38089491
[TBL] [Abstract][Full Text] [Related]
13. The effect of plasmapheresis on blood pressure in voluntary plasma donors.
Rosa-Bray M; Wisdom C; Marier JF; Mouksassi MS; Wada S
Vox Sang; 2015 Jan; 108(1):11-7. PubMed ID: 25169580
[TBL] [Abstract][Full Text] [Related]
14. Ensuring donor safety: is venesecting therapeutic donors to haemoglobin levels below Blood Service guidelines safe?
Lim Z; Bentley P; Olynyk JK
Vox Sang; 2020 May; 115(4):288-292. PubMed ID: 32080874
[TBL] [Abstract][Full Text] [Related]
15. Prospective multicentre study of the effect of voluntary plasmapheresis on plasma cholesterol levels in donors.
Rosa-Bray M; Wisdom C; Wada S; Johnson BR; Grifols-Roura V; Grifols-Lucas V
Vox Sang; 2013 Aug; 105(2):108-15. PubMed ID: 23517282
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donation.
Newman BH; Pichette S; Pichette D; Dzaka E
Transfusion; 2003 May; 43(5):598-603. PubMed ID: 12702180
[TBL] [Abstract][Full Text] [Related]
17. Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram.
Hartmann J; Ragusa MJ; Burchardt ER; Manukyan Z; Popovsky MA; Leitman SF
Transfusion; 2021 Jun; 61(6):1789-1798. PubMed ID: 33760230
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin G levels during collection of large volume plasma for fractionation.
Burkhardt T; Rothe R; Moog R
Transfus Apher Sci; 2017 Jun; 56(3):417-420. PubMed ID: 28454884
[TBL] [Abstract][Full Text] [Related]
19. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.
Buzza M; Marks DC; Capper H; Cassin E; Badcock CA; Reid S; Kwok M; Yang H; Lee J; Corrigan C; Hartkopf-Theis T; Keller A
Transfusion; 2012 Aug; 52(8):1806-13. PubMed ID: 22348664
[TBL] [Abstract][Full Text] [Related]
20. Asking for something different from our donors: factors influencing persuasion success.
Bagot KL; Bove LL; Masser BM; White KM
Transfusion; 2014 Mar; 54(3 Pt 2):848-55. PubMed ID: 24274901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
